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Background and aims 30 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have proved to reduce low 31 
density lipoprotein cholesterol levels in numerous clinical trials. In two large clinical trials 32 
PCSK9 inhibitor treatment reduced the risk of cardiovascular disease. Our aim was to explore 33 
the impact of varying assumptions about clinical effectiveness on health and economic 34 
outcomes for patients with familial hypercholesterolemia. 35 
 36 
Methods 37 
We used a previously published and validated Norwegian model for cardiovascular disease. 38 
The model was updated with recent data from the world’s second largest registry of patients 39 
with genetically confirmed familial hypercholesterolemia. We performed analyses for 24 40 
different subgroups of patients based on age, gender, statin tolerance and previous history 41 
of cardiovascular disease. 42 
 43 
Results 44 
In 1 out of 24 subgroups, PCSK9 inhibitors were cost-effective when effectiveness was 45 
modelled using direct relative efficacy as reported in the FOURIER trial. When using 46 
assumptions as suggested in a recent consensus statement from the European 47 
Atherosclerosis Society, 14 subgroups were cost-effective. 48 
 49 
Conclusion 50 
Cost-effectiveness of PCSK9 inhibitors depends highly on assumptions regarding 51 
effectiveness. Basing assumptions only on randomised controlled trials and not taking into 52 
account varying effect based on baseline cholesterol level results in much fewer groups 53 
being cost-effective. 54 




Familial hypercholesterolemia (FH) is characterized by increased plasma low density 57 
lipoprotein (LDL) cholesterol concentrations and severely increased risk of premature 58 
cardiovascular disease (CVD) (1).  FH is usually caused by mutations in genes encoding key 59 
proteins that clear serum of LDL cholesterol (LDL-C). Heterozygous FH is more common than 60 
previously believed, with a prevalence of approximately 1:250 (2). This would mean that 61 
globally approximately 30 million people suffer from FH, among whom more than 20,000 62 
individuals live in Norway (The United States Census Bureau. Worldometers Current world 63 
population. http://www.worldometers.info/world-population (accessed 01 February 2018)). 64 
Since the cause of the clinical manifestations lies in elevated LDL-C levels, reducing LDL-C is 65 
crucial for preventing CVD events (3).  66 
Using register data we have previously showed that FH patients younger than 40 67 
years old have a tenfold increased risk of CVD events (4). We have also showed that 68 
cardiovascular mortality in this age group is four times higher compared to the Norwegian 69 
population (5). In young patients with CVD, one study recently reported that 71% of those 70 
hospitalized for myocardial infarction (MI) before age 35 years had definite or possible FH 71 
(6). Another study reported that, depending on country, 5-10% of those hospitalized for MI 72 
before 50 years of age had FH (7). The risk of coronary artery disease  in FH was recently 73 
reported to be 22-fold increased in patients with an FH-mutation in combination with an 74 
LDL-C level ≥ 4.9 mmol/L compared with a reference group with LDL-C < 4.2 mmol/L and no 75 
mutation (8).   76 
In 2015, two monoclonal antibodies, proprotein convertase subtilisin/kexin type 9 77 
(PCSK9) inhibitors, alirucomab and evolucomab, were approved by both the European 78 
Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) for use 79 
to lower LDL-C (9). These medications are given as subcutaneous injection every 2 or 4 80 
weeks and lowers LDL-C by 50-60%, also when added to statin treatment (10). Both types 81 
were recently shown to reduce cardiovascular events (11, 12).  82 
Statins in combination with ezetimibe represent the basis of current FH treatment. 83 
This treatment is inexpensive and effective, but even with maximal dose it is often 84 
insufficient to achieve the treatment target in patients with FH due to their particularly high 85 
LDL-C levels. Thus, PCSK9 inhibitors represent a new tool in those who do not reach 86 
treatment targets. The high price of PCSK9 inhibitors, however, raise questions about their 87 
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cost-effectiveness. Using unique register data on CVD events among patients with FH and a 88 
previously published economic model, the aim of this study was to explore how choice of 89 
input variables influence the estimated cost-effectiveness of PCSK-9 inhibitors. We placed 90 
particular focus on the difference between modelling based directly on the recently 91 





The efficacy of PCSK9-inhibitors has been a much-discussed topic in the research literature, 97 
not least after the results from the FOURIER-trial were published. FOURIER is the first large 98 
randomised controlled trial (RCT) with “hard”, clinically relevant outcomes (11).  99 
Essentially, there are two different ways of incorporating effectiveness of PCSK9 inhibitors in 100 
health economic models; either (1) by assuming that relative hazards observed in RCT(s) 101 
apply to all populations, regardless of LDL-C level and other risk factors, or (2) by assuming 102 
that patients with higher LDL-C levels have a larger relative effect of cholesterol reduction as 103 
shown in meta-analyses of randomised controlled trials (13). The first is standard 104 
assumption in evidence-based medicine and most economic evaluations, the latter is based 105 
on results from several meta-analyses, first of statin trials (13), later also confirmed for other 106 
interventions such as ezetimibe and PCSK9-inhibitors (14). Given the convincing evidence of 107 
increasing relative effectiveness of LDL-C reduction with higher baseline LDL-C (14), we 108 
aimed to explore both approaches in modelling the cost-effectiveness of PCSK9 inhibitors. 109 
We therefore incorporated into our model both the hazard ratios observed in the first large-110 
scale RCT currently available for any PCSK9-inhibitor (11) and varying relative effectiveness 111 
depending on baseline LDL-C level. We will in the following refer to the “standard” evidence 112 
based medicine approach as “FOURIER direct”, as this method uses the hazard ratios from 113 
the FOURIER trial directly (Table 1). 114 
With respect to the second approach, a well-recognized way of estimating the effectiveness 115 
of LDL-C reduction is published in a consensus statement by the European Atherosclerosis 116 
Society (EAS). It concludes that a “22% reduction in risk per millimole per litre (mmol/l) 117 
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reduction in LDL-C” summarizes current evidence of “the proportional reduction in short-118 
term risk” (14). EAS proposes the following formula to calculate the relative risk reduction of 119 
atherosclerotic CVD events for patients at different levels of baseline LDL-C (14): 120 
1- RRFLDL*(RRm), where RRF is the relative reduction in CVD risk per mmol/l reduction in LDL-C, 121 
LDL is the baseline LDL-C level and RRm is the treatment effectiveness measured as 122 
percentage reduction in mmol/l. The EAS statement concluded that a Cholesterol Treatment 123 
Trialists’ Collaboration (CTTC) meta-analysis from 2010 (13) represents best current evidence 124 
on the relationship between LDL-C reduction and CVD outcomes, resulting in the number 125 
22% (or RRF = 0.78). The recent FOURIER trial described by Sabatine and colleagues (11) 126 
estimated an RRm of 59%, hence the formula used is 1-0.78LDL*0.59, where LDL in our model 127 
can be varied to analyse different patient groups with different baseline LDL-C. This second 128 
approach is in the following referred to as “EAS consensus”.  129 
As both approaches are plausible in their own merit, one solution may be to incorporate a 130 
midpoint between the two approaches. The hazard ratio reported by Sabatine and 131 
colleagues in the FOURIER trial is the best available evidence, but the baseline LDL-C in that 132 
trial (2.4 mmol/l) is far lower than in most FH populations, even when FH is treated with 133 
potent statins plus ezetimibe (15). With a fixed treatment effectiveness in terms of 134 
percentage LDL-C reduction, the absolute change in mmol/L increase proportionally with 135 
increasing baseline LDL-C levels (13, 14). Thus, given a fixed dose of a lipid lowering 136 
medication, the higher baseline LDL-C and the more LDL will be cleared from the circulation. 137 
To incorporate an alternative that both uses the FOURIER trail and also incorporates 138 
information about LDL-C level in the population, we would have to adjust the observed 139 
hazard ratio (HR) of cardiovascular events based on the assumed baseline LDL-C level in 140 
different populations. This can be done by transforming the observed HR from FOURIER into 141 
a natural logarithmic scale, do calculations on that scale and exponentiate to get back to HR 142 
scale: HRadj = EXP(LN(HRs)-(LDL-LDLs)*RRm*(1-RRF)), where HRS = 0.73, as reported by 143 
Sabatine et al, LDLs = baseline LDL-C observed in Sabatine et al (2.4 mmol/l), and LDL, RRF 144 
and RRm is as defined above. This scenario with an adjustment of the original FOURIER 145 
results according to baseline LDL-C, is in the following called “FOURIER adjusted”. 146 
Although the EAS statement refers to a 22% reduction as the main effect of LDL-C on CVD 147 
(14), there has been suggestions to divide CVD into it’s most common components AMI and 148 
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stroke (16). The mentioned CTTC analyses reports a 29% and 31% reduction of AMI and 149 
stroke respectively. We incorporated this alternative as a fourth modelling option, using the 150 
name “CTTC subgroups”.  151 
In addition to the mentioned four modelling options, there are numerous different ways of 152 
calculating effect of treatment and the number is increasing with increasing publications on 153 
this topic. In Table 1, we have listed 3 further potential analyses that could have been 154 
performed, but were not included in the present model. 155 
We analysed our model for two different levels of LDL-C, representing FH patients who were 156 
statin tolerant and intolerant. For statin tolerant patients, we assumed an average LDL-C of 157 
3.5 mmol/l on current treatment, approximately as reported in the Norwegian FH registry 158 
(17), while for the statin intolerant, we assumed an LDL-C level of 6.0 mmol/l (18). In 159 
addition, we also analysed men and women who had previously experienced a 160 
cardiovascular event, i.e. secondary prevention. For this latter group, we assumed LDL-C 161 
level of 3.5 on average (17) and otherwise similar assumptions as for other patients with 162 
previous CVD event. The assumptions about LDL-C and resulting assumed hazard ratios for 163 
the four different calculation methods are summarized in Table 1. 164 
 165 
 166 
Other modelling assumptions 167 
 168 
Lifetime costs and QALYs were estimated based on the Norwegian Cardiovascular Disease 169 
model (NorCaD)(19), which has been used in several publications previously (20-22). Briefly, 170 
the model is a health state transition model (Markov model) with 4 primary CVD events and 171 
11 health states (Figure 1). Health outcomes are measured until all are dead or 100 years old 172 
and expressed in terms of quality adjusted life years (QALYs). Unit costs are based on market 173 
prices, the Norwegian DRG system and various fee schedules as appropriate (19).   174 
 175 
We used incidence data recently derived from a Norwegian FH registry (4). Unit costs in the 176 
model were updated to 2017 costs based on current prices of pharmaceuticals (as of May 177 
2017) and fees and averages as reported in official documents (23, 24). All costs were 178 
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measured in Norwegian kroner, but reported in European Euros (€) to ease comparison (1 € 179 
= 9.5 NOK). Future health and costs were discounted at 4% per year and analysed using a 180 
health care sector perspective, as described in Norwegian guidelines (25). 181 
 182 
Guidelines developed by the Norwegian Directorate of Health in 2005 (25) state that 183 
interventions are cost-effective for incremental cost-effectiveness ratios (ICERs) below 184 
€62,443 per Quality Adjusted Life Year (QALY). We adjusted this value for inflation and 185 
adopted a threshold of €70,000 per QALY. Although empirical evidence has confirmed this as 186 
an approximate willingness to pay for health gains (26), for comparison, we also evaluated 187 
cost-effectiveness with a threshold of €40,000 per QALY), based on estimation of 188 
opportunity cost of health care resources in the UK (27, 28). 189 
 190 
Sensitivity and analyses 191 
 192 
Lately,  it has been suggested not to discount future health outcomes in Norway (29). 193 
Although this suggestion is not based on all the latest research on this issue (30-32), we 194 
performed scenario analyses without discounting future health to test how this suggestion 195 
may affect conclusions. 196 
 197 
The official price of one year’s use of the least expensive PCSK9 inhibitors is listed at NOK 198 
48,104 (€5064) in the Norwegian Medicines Agency database (Legemiddelverket.no). As 199 
PCSK9 manufacturers offer confidential discounts for the Norwegian health care system, we 200 
performed one-way sensitivity analyses on price. Scenario analyses with up to 50% lower 201 
price are presented for statin intolerant women for four different age groups.  202 
 203 
All uncertain parameters in the NorCaD model, including those added to the model for this 204 
specific analysis, are incorporated as probability distributions. When running simulations of 205 
the model, each uncertain parameter is represented by 1000 realizations from the specified 206 
probability distribution. Probabilistic results are shown only as cost-effectiveness 207 
acceptability curves (CEACs) for 40-year-old statin intolerant women with FH. In the CEAC, 208 
the proportion of simulations in which a PCSK9 inhibitor is cost-effective is shown for all 209 






When we used the EAS consensus approach or the FOURIER adjusted approach for baseline 214 
LDL-C, PCSK9 inhibitors were cost-effective in 15, respectively 13 out of 24 subgroups of FH 215 
patients (Table 2, further details in Appendix table 1). Direct use of the FOURIER HRs yielded 216 
less optimistic results with only one cost-effective subgroup (statin intolerant men aged 60). 217 
With the CTTC subgroup approach PCSK9 treatment was cost-effective in 21 groups.  218 
 219 
When setting the discount rate for outcomes at zero, treatment in all subgroups was cost-220 
effective except when modelling FOURIER results directly (Appendix table 2). With the latter 221 
approach, treatment of 16 of 24 groups was cost-effective, compared with 1 of 24 when 222 
discounting health outcomes at 4%. 223 
 224 
Probabilistic sensitivity analysis of 40-year-old statin intolerant women using FOURIER HRs 225 
directly indicate a zero probability that PCSK9 inhibitors are cost-effective at a cost-226 
effectiveness threshold of €70,000 per QALY, increasing to 80% with FOURIER adjusted for 227 
LDL-C, 95% with the EAS consensus, and 96% with CTTC subgroups (Figure 2). 228 
 229 
One-way sensitivity analysis indicates that price reductions have considerable impact on the 230 
cost-effectiveness of PCSK9 inhibitors. For statin intolerant women, a 50% reduction in the 231 
price would make PCSK9 inhibitors cost-effective for all ages and ways of modelling 232 
effectiveness (at a threshold of €70,000 per QALY), except 30-year-old women modelled 233 
through direct use of FOURIER HRs (Figure 3). Similar analyses are also presented for men 234 





We have shown that cost-effectiveness of PCSK9 inhibitors depends heavily on the way the 240 
effectiveness is modelled. Assuming PCSK9 inhibitors reduces risk of AMI and stroke as 241 
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reported in the FOURIER trial (11) (27% and 21% risk reduction, respectively) results in 242 
PCSK9 inhibitors being cost-effective in only one of 24 analysed risk groups at current prices. 243 
Allowing for reduction of other CVD outcomes or modelling effectiveness as proposed by 244 
EAS (14) may lead to all groups being cost-effective.  245 
 246 
Advances in treatment and prevention of CVD have contributed to considerably decreased 247 
CVD mortality rates during the past four decades. One of the most pronounced consequence 248 
is that CVD to a lesser extent is a middle-age disease today, compared to only a few decades 249 
ago. For patients with FH, however, CVD is still a great threat even in younger age groups (5), 250 
and it is therefore important to start treatment early (33). An example from our own 251 
analyses that illustrates this (Appendix table 1) shows that if treatment for 30-year-olds is 252 
withheld until age 40, up to 0.69 QALYs may be lost on average per person. These QALYs are 253 
lost because the patient develops CVD or dies before becoming 40 years old, corresponding 254 
to for instance 2% dying and loosing 34.5 remaining QALYs.  255 
 256 
Our results are presented from a Norwegian setting based on Norwegian data. Generally, 257 
the transferability of health economic evaluations is limited. However, a recent review of 258 
economic evaluations of PCSK9 inhibitors found that differences between countries were 259 
much smaller than other differences between studies, such as those explored in the present 260 
analysis (34). That review found incremental health effects among FH patients of more than 261 
2 QALYs in two studies and less than 1 QALY in three studies. The two studies with the high 262 
QALY gains concluded that PCSK9 inhibitors are cost-effective, while the other three 263 
concluded PCSK9 inhibitors were not. Similarly, we found that all 32 analyses with a gain of 264 
more than 1 QALY were cost-effective, while most of our analyses with a QALY gain below 1 265 
were not cost-effective (52 out of 64). Based on recent price reductions in some countries, 266 
PCSK9 inhibitors may be more cost-effective in the countries where large rebates have been 267 
given. Official prices (maximum approved price) as reported by the Norwegian Medicines 268 
Agency has, however, not been reduced in the past few years (www.legemiddelverket.no, 269 




Strength and Limitations 272 
In Norway, all individuals with genetically verified FH diagnosis are registered in a patient 273 
registry. As of October 2018, 8220 patients are registered with a pathogenic FH mutation in 274 
Norway, making this registry the second largest in the world of its kind. In the present paper 275 
we used data on hospitalizations and death in a complete cohort of all Norwegian patients 276 
with known FH mutation to estimate the cost-effectiveness of PCSK9 treatment in FH by 277 
applying the previously described health economic model (NORCAD) (19). 278 
 279 
The NorCaD model used in the present work is comprehensive and models specifically some 280 
aspects of cardiovascular disease that are not included in all other cardiovascular models, 281 
such as nursing home care. We have previous shown with the NorCaD model that off-patent 282 
antihypertensive drugs are cost-saving largely due to the reduction in future hospitalization 283 
and nursing home admittance (20). In contrast to other CVD models, NorCaD may capture 284 
reductions in the risk of angina and heart failure. Even though such reductions have yet not 285 
been shown for PCSK9 inhibitors, they are plausible from the LDL level reductions and make 286 
treatment cost-effective in wider groups. These model differences should be noticed when 287 
comparing our results to those published by others (34). 288 
 289 
A high number of genotyped FH patients and the complete follow-up in Norwegian registries 290 
provide a sound basis for the estimates of the present study. All AMI and CHD 291 
hospitalizations all FH patients genotyped in Norway are therefore included in the calculated 292 
incidence.  293 
 294 
Still, the study has several limitations. Information on AMI subtypes (ST-elevation versus 295 
non-ST-elevation) is not available. Further, factors that could influence AMI morbidity and 296 
hospitalization frequencies, e.g.  smoking habits, LDL-C values and statin treatment, were 297 
not accounted for. Further, even though in Norway physicians can request genetic FH-test 298 
free of charge for physicians and patients, the FH register may contain a selected group of 299 
patients. In the present study, we based the assumption of baseline LDL-C level for statin 300 
tolerant on the Norwegian registry that includes all diagnosed with FH in Norway, but we do 301 
not know what proportion of patients who are statin intolerant. This may impact our 302 
assumption about LDL levels among statin tolerant and intolerant patients. The impact of 303 
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this limitation, however, is likely minimal because only a small proportion of the FH patients 304 
are statin intolerant. 305 
 306 
Atherosclerosis is a slow process with lipids accumulating in the arterial wall. LDL-cholesterol 307 
is a major driver of the process and reduction of LDL may slow down and even reverse the 308 
atherosclerosis. Cholesterol years is a concept to calculate the result of the accumulated 309 
cholesterol load on intima, similar to the concept pack-years regarding cigarette smoking. It 310 
was first used to evaluate risk in homozygous patients with FH and total cholesterol values of 311 
20-30 mmol / l (35). In this conceptual understanding, inhibiting the atherosclerosis process 312 
during a study period will provide sustained effects even after the end of the study. The 313 
slowing  of the atherosclerosis process will likely generate health benefits later in life. The 314 
long term follow-up up of statin trials like the WOSCOPS trial provide support for this view 315 
(36) with no significant effect on total mortality the first  6 years, but highly reduced total 316 
mortality 20 years after end of study. The early results of the FOURIER study (11) may 317 
therefore prove 318 
different from the long term results. In several statins trials, like in the 4S study (37), the 319 
survival curves for placebo and statin, did not diverge until about 1.5 years follow-up.  In the 320 
FOURIER study the median duration of follow-up was 2.2 years, which is a short period when 321 
studying the slow process of atherosclerosis. 322 
 323 
Two large RCT’s of PCSK9 inhibitors available (11, 12). Our analyses are based on the trial 324 
that was published first. In large, the two trials did not differ much in results, for instance 325 
both reported a hazard ratio (HR) of 0.85 on their primary outcome. When split into the 326 
detailed outcomes directly used in modelling, the differences are somewhat larger, HRAMI: 327 
0.73 vs 0.86 and HRStroke: 0.79 vs 0.73. Hence, we would have found somewhat different 328 
results if analyses were performed based on ODYSSEY instead of FOURIER.  329 
 330 
As can be seen from the previous paragraph, the primary endpoint in the FOURIER and 331 
ODYSSEY trials indicate a lower effect than the estimates on what we regarded as the most 332 
relevant outcomes in our model; AMI and stroke. If we had used the estimates of effect on 333 
this composite endpoint instead of the endpoints for separate outcomes, we would have 334 
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observed a smaller effect, and therefore that PCSK9 inhibitors were not cost-effective in any 335 
subgroups. 336 
 337 
A recent analysis similar to the CTTC meta-analysis found effects to be somewhat smaller, 338 
with approximately RR of 0.86 instead of 0.78 per mmol/l. as can be seen from our Table 1, 339 
these effect estimates are between the FOURIER direct and FOURIER adjusted, hence we 340 
would likely get somewhere between 1 and 10 risk groups to be cost-effective if this analysis 341 
had been done.   342 
 343 
Conclusions 344 
Our model predictions suggests that PCSK9 inhibitors with the maximum approved price in 345 
Norway are cost-effective for some groups of FH patients, particularly when CVD risk 346 
reduction from LDL level reductions is based on the CTTC meta-analyses as suggested by 347 
EAS. When using clinical relevant endpoints from the FOURIER trial, the proportion of FH 348 
patient groups that is cost-effective to treat with PCSK9 inhibitors is lower. Price discounts 349 
may make it cost-effective in all patient groups. 350 
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Figure legends 473 
Figure 1 Simplified model structure  474 
 475 
Figure 2 Cost-effectiveness acceptability curve for 40-year-old statin intolerant women with 476 
FH 477 
 478 
Figure 3 One-way sensitivity analysis on price reduction of PCSK9 inhibitor for statin 479 
intolerant women in four age groups (upper left: 30 yrs, upper right: 40 yrs, lower left: 50 480 
yrs, lower right: 60 yrs) 481 
 482 




Table 1 Seven different approaches for calculating effectiveness of PCSK9 inhibitors (approaches with * not analyzed) 485 
Statin tolerant 
     




















FOURIER directa 3,5 2,1 1,4 0,73 0,79 
FOURIER adjustedb 3,5 2,1 1,4 0,64 0,69 
EAS consensusb,c 3,5 2,1 1,4 0,60 0,60 
CTTC subgroupsb 3,5 2,1 1,4 0,48 0,45 
*Navarese et al 2018d 
3,5 2,1 1,4 0,72 0,72 
*FOURIER MACEe 3,5 2,1 1,4 0,86 0,86 
*ODYSSEY OUTCOMESf 3,5 1,9 1,6 0,86 0,73 
 
Statin intolerant 
     




















FOURIER directa 6,0 3,5 2,5 0,73 0,79 
FOURIER adjustedb 6,0 3,5 2,5 0,46 0,50 
EAS consensusb,c 6,0 3,5 2,5 0,41 0,41 
CTTC subgroupsb 6,0 3,7 2,3 0,28 0,26 
*Navarese et al 2018d 6,0 3,7 2,3 0,58 0,58 
*FOURIER MACEe 6,0 3,5 2,5 0,86 0,86 
*ODYSSEY OUTCOMESf 6,0 3,3 2,7 0,86 0,73 
a: Same hazard ratio for all levels of baseline LDL-C  
b: Higher hazard ratio with higher baseline LDL-C  
c: Same hazard ratio for AMI and stroke 
18 
 
d: Results from meta-regression by Navarese et al 2018 
e: results on major acute coronary event (MACE) as reported by Sabatine et al 2017 (FOURIER) 
f: Results from Schwartz et al 2018 (ODYSSEY OUTCOMES) 
 486 
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Table 2 Incremental cost-effectiveness ratios (ICER) for 24 different subgroups and 4 different ways of modelling 488 
effectiveness (€/QALY) 489 

















60 108 680 110 144 86 567 143 101 82 648 69 735 
50 142 460 141 823 101 978 99 297 96 322 80 056 
40 219 258 230 669 148 678 140 749 137 530 103 172 
30 346 790 349 803 232 801 221 002 208 313 146 734 
       

















60 75 661 71 350 59 627 67 386 34 728 27 238 
50 100 092 90 023 70 613 63 104 41 790 31 466 
40 155 477 145 181 103 837 86 174 61 203 41 831 
30 247 478 218 744 163 599 133 310 94 486 61 497 
       

















60 66 672 57 436 51 990 49 281 31 003 23 954 
50 88 696 71 541 61 901 49 586 37 590 27 705 
40 138 516 114 990 91 486 65 223 55 413 37 163 
30 221 279 172 159 144 666 99 824 85 939 55 021 
       

















60 40 570 28 359 31 129 21 734 20 175 14 864 
50 55 109 34 165 37 655 24 133 25 145 17 228 
40 87 908 55 130 56 715 28 256 38 060 23 942 
30 142 410 82 098 90 992 42 618 60 133 36 449 
FOURIER = The FOURIER trial (11) 490 
CTTC = Cholesterol treatment trialists collaboration  491 
Green boxes = incremental cost-effectiveness ratios (ICERs) below €70,000 per QALY 492 







Figure 1 Simplified model structure 498 
 499 
Footnotes to Figure 1: 500 
• Established CVD is three different health states based on whether the CVD event was angina, AMI or stroke. 501 
• Stroke Sequelae is two different health states; moderate and severe sequelae 502 
• Heart failure is divided into three health states based on time since heart failure was established 503 
• Dead is two different health states based on whether death was a result of CVD or not. 504 
 505 
 506 
Figure 2 Cost-effectiveness acceptability curve for 40-year-old statin intolerant women with FH 507 
 508 
The estimated threshold for cost-effectiveness is about €40,000 per QALY, while the empirical 509 



































Figure 3 One-way sensitivity analysis on price reduction of PCSK9 inhibitor for statin intolerant women in four age groups 512 
(upper left: 30 yrs, upper right: 40 yrs, lower left: 50 yrs, lower right: 60 yrs) 513 
 514 
 515 
